{"id":15221,"date":"2012-08-20T01:30:00","date_gmt":"2012-08-19T23:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/l%c2%92agosto-nero-della-ricerca\/"},"modified":"2012-08-20T01:30:00","modified_gmt":"2012-08-19T23:30:00","slug":"l%c2%92agosto-nero-della-ricerca","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/l%c2%92agosto-nero-della-ricerca\/","title":{"rendered":"The black August of research"},"content":{"rendered":"

Rome \u2013 It seems like a decidedly unfavorable period for drug trials: well in the last few days four very promising molecules <\/b>they have been abandoned because they are not very effective or with too great side effects, confirming the great difficulty in moving from the laboratory to the patient's bed.<\/p>\n

<\/span><\/p>\n

The latest company in chronological order to have to abandon a clinical study is Amgen, which a few days ago announced the interruption of "phase 3" of the experimentation of a drug for pancreatic cancer <\/b>in the metastatic stage. Ganitumab, this is the name of the product, \u00abdid not show any particular side effects\u00bb, reads a company release, but was unable to improve the patient's prognosis: \u00abTen years ago it was thought that drugs like this, that affect a hormone called insulin-like growth factor, were the most interesting news in oncology \u2013 explained Leonard Saltz, a researcher at Memorial Sloan-Kettering Cancer Center to the New York Times \u2013 But at least 11 companies that had molecules similar to this one in development none have had positive results.<\/p>\n

<\/span><\/p>\n

Before Amgen, it was the companies Johnson & Johnson and Pfizer, at the beginning of last week, which stopped the tests on Bapineuzumab, a drug developed jointly which was supposed to stop the development of Alzheimer's <\/b>in patients who had a mild or moderate form of the disease: again, the decision was made by the poor results, although a trial on patients who do not yet have the disease should still take place.<\/p>\n

<\/span><\/p>\n

A few days later it was Merck who announced that, for unspecified "economic reasons", the development of a drug against cholesterol <\/b>had been discontinued.<\/p>\n

<\/span><\/p>\n

However, the week before, Britsol-Myers-Squibb, another pharmaceutical multinational, had inaugurated this "black August" of research, announcing the halt to the experimentation of a drug for the treatment of hepatitis C<\/b>: in this case it was not the lack of efficacy that led to the decision, but the fact that at least one of the patients undergoing the treatment had a problem with<\/p>","protected":false},"excerpt":{"rendered":"

Roma – Sembra un periodo decisamente sfavorevole per le sperimentazioni dei farmaci: negli ultimi giorni ben quattro molecole molto promettenti sono state abbandonate perché poco efficaci o con effetti collaterali troppo grandi, a conferma della grande difficoltà nel passare dal laboratorio al letto del paziente. L’ultima compagnia in ordine di tempo a dover abbandonare uno …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15221"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15221\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}